CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Centro de Atención Médica dedicado a la conducción de Estudios de Investigación Clínica en diferentes fases de desarrollo con más de 10 años de experiencia en diversas áreas de especialización.Av. Pueyrredón 1746 2° A, C1119 Cdad. Autónoma de Buenos Aires, Argentina
Websitehttp://www.ciprec.org/es
Select an option
I am a doctor
I am a sponsor
Specializations
Diabetes
Gastroparesia diabética
Obesidad
Colangitis biliar primaria
Cardiovascular
Enfermedad renal crónica
Hígado graso
Covid-19
Our team
Medical staff
Eliana Serrano
Fernando Guerlloy
Irene Copati
Agustina Bandoni
Agustina Filograsso
Evelyn Garre
Lucia Rey
Vanesa Espinosa
Amanda Gomez
Fernando Guerlloy - C
César Zaidman
Angela Romero Zarante
César Javier Zaidman
Fernando Gruz
Ezequiel Slutsky
Pablo Olivera Sendra
Noelia Broqua
Tania Zarowsky
Mariano Gabriel Marini
Open studies
Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) - CAMBRIA-2 - AstraZenecaSee more
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence - ELEGANT - Stemline Therapeutics, Inc.See more
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease - FourLight-3 - PfizerSee more
Arterial hypertension
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. - BaxDuo-Arctic - AstraZenecaSee more
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) - ls (ATTAIN-HYPERTENSION - Eli Lilly and CompanySee more
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 - ATTAIN-HYPERTENSION - Eli Lilly and CompanySee more
Obesity
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) - ls (ATTAIN-HYPERTENSION - Eli Lilly and CompanySee more
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 - ATTAIN-HYPERTENSION - Eli Lilly and CompanySee more
Renal disease
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. - BaxDuo-Arctic - AstraZenecaSee more
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Cardiovascular disease
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and CompanySee more
Cholangitis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead SciencesSee more
Cirrhosis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead SciencesSee more
Dermatitis
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) - DUPLEX-AD - Janssen Research & Development, LLCSee more
Elevated Lipoprotein A
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and CompanySee more
Fatty Liver
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis - Kowa Research Institute, Inc.See more
Fatty liver/nash
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis - Kowa Research Institute, Inc.See more
Hidradenitis suppurativa
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) - Merck Sharp & Dohme LLCSee more
